Prognostic Factors and Progression Biomarkers in AL Amyloidosis: Mapping Current Knowledge and Critical Gaps - PubMed
8 hours ago
- #prognostic biomarkers
- #AL amyloidosis
- #daratumumab
- Daratumumab-based regimens have revolutionized AL amyloidosis treatment, achieving 76% five-year overall survival in the ANDROMEDA trial.
- Current prognostic models are outdated as they were developed using suboptimal therapies, creating a gap with contemporary outcomes.
- Prognostic factors in AL amyloidosis are categorized into disease-specific (clone-related and organ-related) and patient-specific factors.
- Traditional biomarkers like dFLC and bone marrow plasma cell burden are losing prognostic significance with effective clone-directed therapies.
- Emerging biomarkers include minimal residual disease by free light chain mass spectrometry, cardiac imaging parameters like global longitudinal strain, and functional measures.
- There is an urgent need for validation studies and refined prognostic models to identify high-risk patients for tailored interventions.